Prevalence of Hepatopancreatic Injury and Clinical Outcomes in Patients with COVID-19 in USA
Ocala Regional Medical Center
sars-cov-2, coronavirus infections, COVID-19, hepatopancreatic injury, liver, pancreas, mortality
Digestive System Diseases | Emergency Medicine | Virus Diseases
(1) To determine the prevalence of hepatopancreatic injury in coronavirus disease 2019 (COVID-19) patients. (2) To correlate hepatopancreatic injury in COVID-19 with mortality, disease severity, and length of stay in this cohort.
Forty-five thousand three hundred sixty patients were included in the analysis, 62.82% of which had either hepatic or pancreatic injury. There was a significant upward trend in transaminases, alkaline phosphatase, prothrombin time, bilirubin, lactate dehydrogenase, and lipase and a downward trend in albumin with an increase in disease severity. COVID-19-positive patients with hepato-pancreatic injury have a significantly higher mortality (OR 3.39, 95%CI 3.15–3.65) after controlling for the differences in age, sex, race/ethnicity, liver cirrhosis, and medication exposures. They also have increased disease severity (OR 2.7, 95%CI 2.5–2.9 critical vs mild/moderate; OR 1.4, 95% CI 1.3–1.5 severe vs mild/moderate) and longer hospital length of stay (2 days).
COVID-19 can cause liver injury. Mortality, disease severity, and hospital length of stay are increased in COVID-19 patients with hepatopancreatic injury.
Publisher or Conference
International Journal of Emergency Medicine
Rastogi V, Banwait R, Singh D, et al. Prevalence of hepatopancreatic injury and clinical outcomes in patients with COVID-19 in USA. Int J Emerg Med. 2021;14():68. doi: 10.1186/s12245-021-00393-2